Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects

Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin-based drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical version of psilocybin is designed to avoid inducing the hallucinogenic effects commonly associated with "magic" mushrooms, paving the way for more accessible therapies.

The company recently announced that PSIL-006 had successfully cleared a key safety milestone in preclinical studies, demonstrating a "strong" safety profile. This progress marks an important step toward future human trials and, potentially, FDA approval. If successful, the drug could address frontotemporal dementia (FTD), a condition that affects nearly 60 million Americans and currently lacks any FDA-approved treatments.

Read Also: ‘Psychedelics Are Here To Stay And They Belong To Everyone,’ Says Mycopreneur’s Dennis Walker

Advancing Dementia Treatment Without Psychedelic Effects

Psilera's PSIL-006 was tested in models that mimic FTD, showing promising improvements in memory, sleep, and learning. However, further research and rigorous clinical trials, including human testing, will be needed before the drug can be considered for FDA approval.

What makes PSIL-006 unique in the field of psychedelic-based treatments is its trip-free design. Traditional psychedelics like MDMA, LSD, and psilocybin have been challenging to study in double-blind placebo trials due to their powerful effects, which make it obvious to both patients and researchers whether they have received the real drug or a placebo. This limitation has long hindered their progression through the clinical approval process.

Because PSIL-006 lacks the typical "trip" or any psychoactive effects of psilocybin, it may allow for more reliable double-blind trials, an essential element for achieving FDA approval. The drug is designed to deliver the therapeutic benefits of psilocybin without the mind-altering experiences, making it safer and more practical for patients with mental health sensitivities or dementia, who could otherwise experience confusion or anxiety during a psychedelic trip.

A New Frontier In Psychedelic Medicine

As Double Blind reported, the development of non-psychedelic versions of drugs like psilocybin is gaining momentum. Other companies, such as Boston-based Onsero Therapeutics and Delix Therapeutics are also working on trip-free psychedelic-based drugs. These compounds target the 5-HT2A receptor, the same receptor affected by psychedelics, without triggering hallucinations. As Aaron Koenig, chief medical officer at Delix Therapeutics, explained to Scientific American, "Some patients are terrified when they go through these trips, and it's not something they ever want to do again."

Creating trip-free versions of these drugs offers additional benefits, including the possibility of self-administration at home rather than under clinical supervision. This could make treatment more accessible and convenient, particularly for long-term or chronic conditions like dementia.

The Future Of Non-Psychedelic Therapies

While the therapeutic potential of psychedelic drugs is well-documented, the focus on developing non-psychedelic derivatives has opened new avenues for treatment. These innovations are being closely watched in a multi-billion-dollar industry driven by growing demand for mental health therapies. As clinical trials progress, PSIL-006 and other non-psychedelic therapies could significantly impact the future of mental health and dementia care, addressing a critical need in the U.S., where around 60 million people are affected by mental health issues.

Cover image made with Ai